home / stock / sabs / sabs news

SABS News and Press, SAB Biotherapeutics Inc. From 11/21/22

Stock Information
Company Name: SAB Biotherapeutics Inc.
Stock Symbol: SABS
Market: NASDAQ
Website: sabbiotherapeutics.com
Menu
SABS SABS Quote SABS Short SABS News SABS Articles SABS Message Board
Get SABS Alerts

News, Short Squeeze, Breakout and More Instantly...
SABS - SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

SIOUX FALLS, S.D., Nov. 21, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need f...
SABS - SAB Biotherapeutics GAAP EPS of -$0.16 misses by $0.02

SAB Biotherapeutics press release ( NASDAQ: SABS ): Q3 GAAP EPS of -$0.16 misses by $0.02 . Cash and cash equivalents were $8.3 million as of September 30, 2022, compared to $16.6 million on June 30, 2022, which was driven primarily by SAB’s third quarter cash o...

SABS - SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for ...

SABS - SAB Biotherapeutics Presents 'Novel Biologic Therapeutics for Infectious Diseases' at U.S. Pharma Partnering Summit 2022

SIOUX FALLS, S.D., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the n...
SABS - SAB Biotherapeutics Presents Overview of DiversitAb(TM) Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

SIOUX FALLS, S.D., Nov. 03, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need...

SABS - SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies ...

SABS - SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

SAB Biotherapeutics ( NASDAQ: SABS ) is trading 5.6% higher after the company said its fully-human polyclonal antibody platform maintains efficacy against multiple variants of several highly mutating viruses. A Phase 2a challenge trial showed SAB-176 reduced t...
SABS - SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron

SIOUX FALLS, S.D., Sept. 28, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for ...

SABS - SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185's Effectiveness Against Multiple COVID-19 Variants

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for ...

SABS - SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

SAB Biotherapeutics press release ( NASDAQ: SABS ): Q2 GAAP EPS of -$0.11 beats by $0.03 . Cash and cash equivalents were $16.6 million as of June 30, 2022, compared to $22.4 million on March 31, 2022, which was driven primarily by $0.7 million in further capital expan...
Previous 10 Next 10